As the GLP-1 drug race moves toward easier-to-take oral treatments, Lilly’s new pill, taken once daily with no food or water restrictions, appears more convenient than Novo’s own oral GLP-1, while also delivering weight loss and blood sugar results that rival Novo’s wildly popular injectable, Ozempic.
Though Novo Nordisk got a brief boost last week after Pfizer scrapped a new obesity pill effort, Lilly’s latest entry is adding to the mounting pressure on the drugmaker. Just last month, a trial of Novo’s new weight-loss injectable disappointed investors — helping erase a third of its market value this year and leading it to cede its crown as Europe’s most valuable company.
As the GLP-1 drug race moves toward easier-to-take oral treatments, Lilly’s new pill, taken once daily with no food or water restrictions, appears more convenient than Novo’s own oral GLP-1, while also delivering weight loss and blood sugar results that rival Novo’s wildly popular injectable, Ozempic.
Though Novo Nordisk got a brief boost last week after Pfizer scrapped a new obesity pill effort, Lilly’s latest entry is adding to the mounting pressure on the drugmaker. Just last month, a trial of Novo’s new weight-loss injectable disappointed investors — helping erase a third of its market value this year and leading it to cede its crown as Europe’s most valuable company.
